Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-08

Clinical Trial Update: Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating intensified treatment with carfilzomib in multiple myeloma patients who remain PET-positive after first-line therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Carfilzomib (carfilzomib)

Snippet

Sponsor: Oslo University Hospital | Conditions: Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING